This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentEventsMaterialsVideosLet's connectLet's ConnectPfizer medical informationOnConnect
DosingDosingDosing ScheduleDose ModificationsAboutAboutStudy MethodologyEfficacy & SafetyEfficacy & Safety Progression-free Survival & Objective Response RateCNS EfficacyGuidelinesSafety TablesSafety Overview

Menu

Close

DosingDosingDosing ScheduleDose ModificationsTherapy ManagementTherapy ManagementHyperlipidaemiaOedemaILD/PneumonitisCNS EffectsSummarySupport & ServicesSupport & ServicesSummary of Prescribing InformationDownloadable ResourcesEvents & WebinarsVideosUseful Links

LORBRIQUA® (lorlatinib) is indicated for the treatment of adult patients with ALK+ metastatic NSCLC.1

Study Methodology

CROWN trial2
 

LORBRIQUA® is a third-generation ALK inhibitor that was evaluated in a global, open-label, randomised, multicentre, Phase 3 trial2

 Brand A-Z

Adapted from Shaw AT, et al. 2020.

    

Primary endpoint

  • PFS by BICR

Secondary endpoints:

  • PFS by investigator
  • ORR by BICR and investigator
  • IC-ORR, DoR and IC-DoR by BICR
  • IC time to progression by BICR
  • OS
  • Safety
  • QoL

Baseline Characteristics2

  

  

Adapted from Shaw AT, et al. 2020.

  

  

*Based on the BICR assessment.

   

ALK, anaplastic lymphoma kinase; ALK+, anaplastic lymphoma kinase-positive; BICR, blinded independent central review; BID, twice a day; CNS, central nervous system; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; IC, intracranial; IC-DoR, intracranial duration of response; IC-ORR, intracranial overall response rate; IQR, interquartile range; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; QD, once a day; QoL, quality of life; RECIST v1.1, Response Evaluation Criteria in Solid Tumours version 1.1.

   

References:

Lorbriqua. Local product document. Pfizer; 2021. LPD Version 7.0  LPDLOR102022.Shaw AT, Bauer TM, de Marinis F, et al. CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.

   

Please click the Prescribing Information link to view the safety and adverse events information of LORBRIQUA®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.​​​​​​

   

PP-LOR-IND-0129 June 2022

About Brand A-Z

CNS Efficacy

82% IC response rate with LORBRIQUA® in patients with measurable brain metastases at baseline (BICR assessed)

 Learn moreLoading
Brand A-Z

Efficacy & Safety


 Learn moreLoading
Contact Center for Health Care Professionals | Monday to Saturday 9:00 AM to 6:00 PM IST(exlcuding public holidays)

0008000503188

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign OutThese pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.

Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
PP-LOR-IND-0129

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2024 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0597  01 Mar 2024Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0597  01 Mar 2024